OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Psychiatry is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Broadening the Parameters of Clinical High Risk for Psychosis	465
2024 Annual Meeting: Presidential Address	197
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	135
Evaluating Associations Between Cannabis and Heroin Use	128
Treating Pathologies of the Will	126
Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia	122
Mental Health Disparities Research: An Introduction to New Directions	112
Highlights From the Residents’ Journal: December 2021	109
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	108
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	105
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	96
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	94
Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology	93
Depression, Inflammation, and Postpartum Psychosis	89
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	89
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	89
Intentional Drug Overdose Deaths in the United States	86
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	86
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	83
Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	83
On the Genetic and Environmental Relationship Between Suicide Attempt and Death by Suicide	82
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis	80
New Insights Into Psychotic Disorders	80
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	80
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	77

12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	73
2024 Annual Meeting: CEO and Medical Director’s Address	71
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	71
Highlights From the Residents’ Journal: September 2021	67
Correcting Overestimations in Self-Harm Visit Data	66
Highlights From the Residents’ Journal: September 2024	65
APA Council Reports	65
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	62
Correction to Poirot et al.	59
Corrigendum to Morley et al.	59
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	58
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	57
Suicide and the Menstrual Cycle	57
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	55
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression	54
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	53
Familial Risk of Postpartum Psychosis	53
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	53
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	52
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	51
The First Large GWAS Meta-Analysis for Postpartum Depression	51
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	50
Coordinate Network Mapping: An Emerging Approach for Morphometric Meta-Analysis	50
Whole Brain White Matter Tract Deviation and Idiosyncrasy From Normative Development in Autism and ADHD and Unaffected Siblings Link With Dimensions of Psychopathology and Cognition	50
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial	49